Investor Resources
Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 6, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – November 6, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...
-
Nov 5, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – November 5, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...
-
Oct 30, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – October 30, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...
-
Sep 21, 2020
FDA assigns PDUFA target action date of March 5, 2021 LAVAL, CANADA, and CAMBRIDGE, ENGLAND – September 21, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the...
-
Sep 9, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – September 9, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...